Concepedia

Publication | Open Access

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

DOIFull Paper Access

477

Citations

25

References

2013

Year

Yuqiao Shen, Farah Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard Elliott, Bing Wang, Christopher J. Lord, Leonard Post, Alan Ashworth
Clinical Cancer Research

Abstract

BMN 673 is currently in early-phase clinical development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.

References

YearCitations

Page 1